Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A safety and efficacy study of TJ103 (TG103) injection for type 2 diabetes treatment

Next Previous
Trial Profile

A safety and efficacy study of TJ103 (TG103) injection for type 2 diabetes treatment

Planning
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2018

At a glance

  • Drugs GX G6 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 21 Aug 2018 New trial record
    • 09 Aug 2018 According to I-MAB Biopharma media release, the company has received clinical trial approval from China National Drug Administration (CNDA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top